SCHEMBL4677311

SCHEMBL4677311

CCN(CC)CCCCNc1nnc2cc(-c3cc(OC)nc(OC)c3)c(=O)n(CC)c2n1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FGFR2 P21802 12/20 0.49
FGFR1 P11362 12/20 0.49
FGFR4 P22455 9/20 0.49
FGFR3 P22607 9/20 0.49
KDR P35968 9/20 0.49
RIPK2 O43353 2/20 0.42
ACVR1 Q04771 2/20 0.42
NOD2 Q9HC29 2/20 0.42
FLT1 P17948 5/20 0.39
FLT4 P35916 5/20 0.39
SRC P12931 5/20 0.39
EGFR P00533 1/20 0.39
GLA P06280 1/20 0.38
CSK P41240 1/20 0.38
KMT2A Q03164 1/20 0.38
ATM Q13315 1/20 0.38
BTK Q06187 2/20 0.37
LYN P07948 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4677307 0.91 FGFR2 (0.61) FGFR2FGFR1FGFR4FGFR3KDR
SCHEMBL4677846 0.87 FGFR1 (0.41) FGFR2FGFR1FGFR4FGFR3KDR
SCHEMBL4679189 0.85 PIK3CA (0.44) FGFR2FGFR1FGFR4FGFR3KDR
SCHEMBL4675946 0.84 FGFR1 (0.43) FGFR2FGFR1FGFR4FGFR3KDR
SCHEMBL4676374 0.83 FGFR1 (0.52) FGFR2FGFR1FGFR4FGFR3KDR
SCHEMBL4676817 0.83 FGFR1 (0.44) FGFR2FGFR1FGFR4FGFR3KDR
SCHEMBL4679454 0.82 FGFR1 (0.46) FGFR2FGFR1FGFR4FGFR3KDR
SCHEMBL4676544 0.81 FGFR1 (0.48) FGFR2FGFR1FGFR4FGFR3KDR
SCHEMBL4679629 0.79 RIPK2 (0.66) FGFR2FGFR1FGFR4FGFR3KDR
SCHEMBL4679756 0.76 PIK3CA (0.48) FGFR2FGFR1FGFR4FGFR3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1195378-B1 Pyridotriazines and pyridopyridazines WARNER LAMBERT CO (US) 2008-01-23 EP claimed
US-6683183-B2 BICYCLIC HETEROCYCLES THAT INHIBIT CYCLIN-DEPENDENT KINASE OR TYROSINE KINASE ENZYMES, OR BOTH, FOR TREATMENT OF PROLIFERATIVE DISORDERS WARNER-LAMBERT COMPANY 2004-01-27 US claimed
US-20020061865-A1 Pyridotriazines and pyridopyridazines KRAMER JAMES BERNARD (US) 2002-05-23 US claimed
EP-1195378-A1 Pyridotriazines and pyridopyridazines WARNER-LAMBERT COMPANY (US) 2002-04-10 EP claimed
EP-1195378-B1 Pyridotriazines and pyridopyridazines WARNER LAMBERT CO (US) 2008-01-23 EP disclosed
US-6683183-B2 BICYCLIC HETEROCYCLES THAT INHIBIT CYCLIN-DEPENDENT KINASE OR TYROSINE KINASE ENZYMES, OR BOTH, FOR TREATMENT OF PROLIFERATIVE DISORDERS WARNER-LAMBERT COMPANY 2004-01-27 US disclosed
US-20020061865-A1 Pyridotriazines and pyridopyridazines KRAMER JAMES BERNARD (US) 2002-05-23 US disclosed
EP-1195378-A1 Pyridotriazines and pyridopyridazines WARNER-LAMBERT COMPANY (US) 2002-04-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061865-A1 Pyridotriazines and pyridopyridazines CDK1, CDK4, CDK2 FGFR2 694/4885FGFR1 194/4885FGFR4 403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.